Back to results
US 2019/0195892 A1Published application
Method of distinguishing between different neurodegenerative diseases
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsMichael SIERKS, Stephanie WILLIAMS
Life of this patent
Estimating the term…
Abstract
The invention provides diagnostic tests to distinguish between different pre-symptomatic neurodegenerative diseases.
Claims18
A method of determining a quantity of a target oligomer in a biological fluid sample from a patient to determine an increased likelihood of having or developing a neurodegenerative disease, comprising;
- (a) contacting the sample to a solid support, wherein the solid support is coated with a capture agent specific for the target oligomer and is blocked with a blocking agent to form a bound sample;
- (b) incubating the bound sample;
- (c) contacting the bound sample with labelled phage specific for the target oligomer to form a labeled bound sample;
- (d) contacting the labeled bound sample with labeled detection agent to form a visualizable sample;
- and
- (e) comparing the quantity of the visualizable sample and to a control to determine the quantity of the target oligomer.
3 more elements
A method of distinguishing between different neurodegenerative diseases in a biological fluid sample from a patient, comprising:
- (a) contacting the sample to a solid support, wherein the solid support comprises two or more locations, wherein each location is coated with a different capture agent specific for a target oligomer, and wherein the solid support is blocked with a blocking agent to form a bound sample;
- (b) incubating the bound sample;
- (c) contacting the bound sample with two or more labelled phages, wherein each labelled phage is specific for a single target oligomer to form labeled bound samples;
- (d) contacting the labeled bound samples with labeled detection agent to form a visualizable samples;
- and
- (e) comparing the quantity of the visualizable samples to quantities of controls to determine the quantity of each target oligomer;
- wherein an increase in toxic oligomeric Aβ is indicative of the patient having early AD, wherein an increase in oligomeric Aβ and tau aggregates is indicative of later stage AD,
- wherein an increase in oligomeric tau but not oligomeric Aβ is indicative a tauopathy;
- wherein an increase in oligomeric a-syn is indicative of Parkinson's disease;
- and
- wherein an increase oligomeric Aβ and a-syn is indicative of Dementia with Lewy Bodies (DLB).
8 more elements
Dependencies are inferred from the claim text.